EP2844756A4 - MODULATION OF IMMUNE RESPONSES - Google Patents

MODULATION OF IMMUNE RESPONSES

Info

Publication number
EP2844756A4
EP2844756A4 EP13784572.3A EP13784572A EP2844756A4 EP 2844756 A4 EP2844756 A4 EP 2844756A4 EP 13784572 A EP13784572 A EP 13784572A EP 2844756 A4 EP2844756 A4 EP 2844756A4
Authority
EP
European Patent Office
Prior art keywords
modulation
immune responses
immune
responses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP13784572.3A
Other languages
German (de)
French (fr)
Other versions
EP2844756A1 (en
Inventor
Glen N Barber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/460,408 external-priority patent/US20130039933A1/en
Application filed by Individual filed Critical Individual
Publication of EP2844756A1 publication Critical patent/EP2844756A1/en
Publication of EP2844756A4 publication Critical patent/EP2844756A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP13784572.3A 2012-04-30 2013-04-30 MODULATION OF IMMUNE RESPONSES Ceased EP2844756A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/460,408 US20130039933A1 (en) 2008-08-04 2012-04-30 Sting (stimulator of interferon genes), a regulator of innate immune responses
PCT/US2013/038840 WO2013166000A1 (en) 2012-04-30 2013-04-30 Modulating immune responses

Publications (2)

Publication Number Publication Date
EP2844756A1 EP2844756A1 (en) 2015-03-11
EP2844756A4 true EP2844756A4 (en) 2016-02-24

Family

ID=49514802

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13784572.3A Ceased EP2844756A4 (en) 2012-04-30 2013-04-30 MODULATION OF IMMUNE RESPONSES

Country Status (7)

Country Link
EP (1) EP2844756A4 (en)
JP (1) JP2015516989A (en)
KR (1) KR20150004416A (en)
CN (1) CN104540945A (en)
AU (1) AU2013256468A1 (en)
CA (1) CA2907616A1 (en)
WO (1) WO2013166000A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2858722B8 (en) 2012-06-08 2018-02-21 Aduro BioTech, Inc. Compostions and methods for cancer immunotherapy
SG11201502796RA (en) 2012-12-13 2015-05-28 Aduro Biotech Inc Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
JP2016506408A (en) 2012-12-19 2016-03-03 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Pharmaceutical targeting of mammalian cyclic dinucleotide signaling pathways
JP2016524593A (en) 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター Compositions and methods for altering second messenger signaling
CN105377867B (en) 2013-05-03 2019-11-12 加利福尼亚大学董事会 Cyclic dinucleotide induction of type I interferon
CU24377B1 (en) 2013-05-18 2018-12-05 Aduro Biotech Inc CYCLIC PURINE DINUCLEOTIDES AND COMPOSITIONS OF THE SAME USEFULS TO INDICATE THE PRODUCTION OF TYPE I INTERFERON DEPENDENTS OF STING
EP2996472B1 (en) 2013-05-18 2019-03-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
EP3152217B1 (en) 2014-06-04 2018-08-01 GlaxoSmithKline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
TWI706958B (en) 2015-03-10 2020-10-11 美商艾杜諾生物科技公司 Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
JP6411676B2 (en) 2015-12-03 2018-10-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Cyclic purine dinucleotides as regulators of STING
CN106540260A (en) * 2015-12-09 2017-03-29 聊城市奥润生物医药科技有限公司 Interferon gene stimulatory protein(SP)（STING）Application of the agonist in anti-alzheimer's disease
IL280430B2 (en) 2016-03-18 2023-11-01 Univ Texas Cyclic di-nucleotide compounds and methods of use
CN106539757A (en) * 2016-03-20 2017-03-29 聊城市奥润生物医药科技有限公司 Application of the ring dinucleotide cGAMP- liposomees in antitumor
SG10201900628RA (en) 2016-04-07 2019-02-27 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
MX2019009070A (en) 2017-02-01 2019-10-30 Modernatx Inc Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides.
CN106667914B (en) * 2017-03-13 2022-02-01 杭州星鳌生物科技有限公司 Composition of targeted liposome-cyclic dinucleotide, preparation method and application of targeted liposome-cyclic dinucleotide in resisting tumors
AU2018344902B2 (en) 2017-10-05 2021-06-03 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING) useful in treating HIV
CA3078309A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Methods for administering sting agonists
US11377440B2 (en) 2017-10-05 2022-07-05 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING)
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
CN112351778B (en) 2018-06-28 2023-04-04 江苏恒瑞医药股份有限公司 Fused tricyclic heterocycles and therapeutic uses thereof
TW202104214A (en) 2019-04-05 2021-02-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 Chemical compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
WO2021119753A1 (en) 2019-12-18 2021-06-24 Ctxt Pty Limited Compounds
AU2020405068A1 (en) 2019-12-18 2022-07-07 Stinginn Llc Substituted 1,2, 4-triazoles and methods of use
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use
WO2025262266A1 (en) 2024-06-21 2025-12-26 Institut National de la Santé et de la Recherche Médicale Methods of determining the clinical phenotype of patients suffering from hidradenitis suppurativa

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110262485A1 (en) * 2008-08-04 2011-10-27 University Of Miami Sting (stimulator of interferon genes), a regulator of innate immune responses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110262485A1 (en) * 2008-08-04 2011-10-27 University Of Miami Sting (stimulator of interferon genes), a regulator of innate immune responses

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ABE TAKAYUKI ET AL: "STING Recognition of Cytoplasmic DNA Instigates Cellular Defense", MOLECULAR CELL, CELL PRESS, CAMBRIDGE, MA, US, vol. 50, no. 1, 7 March 2013 (2013-03-07), pages 5 - 15, XP028547914, ISSN: 1097-2765, DOI: 10.1016/J.MOLCEL.2013.01.039 *
MARCO PRINZ ET AL: "Type I Interferons as Ambiguous Modulators of Chronic Inflammation in the Central Nervous System", FRONTIERS IN IMMUNOLOGY, vol. 3, 1 January 2012 (2012-01-01), XP055211634, DOI: 10.3389/fimmu.2012.00067 *
SCHULTZ J ET AL: "UPDATE ON ANTIVIRAL DNA VACCINE RESEARCH (1998-2000)", INTERVIROL, KARGER, CH, vol. 43, no. 4-06, 1 January 2000 (2000-01-01), pages 197 - 217, XP009055445, ISSN: 0300-5526, DOI: 10.1159/000053988 *
See also references of WO2013166000A1 *

Also Published As

Publication number Publication date
CA2907616A1 (en) 2013-11-07
KR20150004416A (en) 2015-01-12
JP2015516989A (en) 2015-06-18
CN104540945A (en) 2015-04-22
AU2013256468A1 (en) 2014-12-04
WO2013166000A1 (en) 2013-11-07
EP2844756A1 (en) 2015-03-11

Similar Documents

Publication Publication Date Title
EP2879709A4 (en) MODULATION OF THE IMMUNE RESPONSE
EP2807309A4 (en) CRÉPINE DE DIDANGE
EP2839005A4 (en) MICROARN MODULATORS OF THERMOGENESIS
EP2900673A4 (en) MODULATION OF IRE1
CO6801776A2 (en) Cosmetic
EP2898326A4 (en) EFFECTIVE MODULATED IMAGING
DK3461895T3 (en) MODULATION OF UBE3A-ATS EXPRESSION
EP2817275A4 (en) CONVERSION OF LIPIDS
EP2881022A4 (en) USTENSILE COOKING
AR092198A1 (en) DERIVATIVES OF PIRAZOLOPIRIMIDINAS
EP2873453A4 (en) STIRRER
EP2870879A4 (en) ENHANCING FOOD PROPERTY SUBSTANCE
EP2888965A4 (en) KIMONO
ES2439418B1 (en) Cooking Field Device
EP2765913A4 (en) LANCET
EP2920756A4 (en) KNOWLEDGE OF CUSTOMERS
EP2915535A4 (en) INDUCER OF IMMUNE TOLERANCE
DE112013006030A5 (en) clutch
EP2873417A4 (en) INDUCER OF IMMUNE TOLERANCE
EP2916362A4 (en) Photodiode
HUE049492T2 (en) Modulation of privacy
ES2439417B1 (en) Cooking Field Device
PT2820042T (en) IGG-STIMULATED REMYELINIZATION OF PERIPHERAL NERVES
DE112013005253A5 (en) Food Hacker
FR2994309B1 (en) SIMULATION OF INSULAR KARSTIFICATION

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20141201

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/11 20060101AFI20150914BHEP

Ipc: A61K 31/711 20060101ALI20150914BHEP

Ipc: A61P 35/00 20060101ALI20150914BHEP

Ipc: A61K 31/713 20060101ALI20150914BHEP

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20160126

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20160120BHEP

Ipc: A61K 31/711 20060101ALI20160120BHEP

Ipc: C12N 15/11 20060101AFI20160120BHEP

Ipc: A61K 31/713 20060101ALI20160120BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170131

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20180625